TY - JOUR
T1 - Treating mild gestational diabetes mellitus
T2 - A cost-effectiveness analysis
AU - Ohno, Mika S.
AU - Sparks, Teresa N.
AU - Cheng, Yvonne W.
AU - Caughey, Aaron B.
N1 - Funding Information:
Y.W.C. is supported by the University of California, San Francisco, Women's Reproductive Health Research Career Development Award funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (Grant no. K12 HD001262 ).
PY - 2011/9
Y1 - 2011/9
N2 - Objective: This study investigated the cost-effectiveness of treating mild gestational diabetes mellitus (GDM). Study Design: A decision analytic model was built to compare treating vs not treating mild GDM. The primary outcome was the incremental cost per quality-adjusted life year (QALY). All probabilities, costs, and benefits were derived from the literature. Base case, sensitivity analyses, and a Monte Carlo simulation were performed. Results: Treating mild GDM was more expensive, more effective, and cost-effective at $20,412 per QALY. Treatment remained cost-effective when the incremental cost to treat GDM was less than $3555 or if treatment met at least 49% of its reported efficacy at the baseline cost to treat of $1786. Conclusion: Treating mild GDM is cost-effective in terms of improving maternal and neonatal outcomes including decreased rates of preeclampsia, cesarean sections, macrosomia, shoulder dystocia, permanent and transient brachial plexus injury, neonatal hypoglycemia, neonatal hyperbilirubinemia, and neonatal intensive care unit admissions.
AB - Objective: This study investigated the cost-effectiveness of treating mild gestational diabetes mellitus (GDM). Study Design: A decision analytic model was built to compare treating vs not treating mild GDM. The primary outcome was the incremental cost per quality-adjusted life year (QALY). All probabilities, costs, and benefits were derived from the literature. Base case, sensitivity analyses, and a Monte Carlo simulation were performed. Results: Treating mild GDM was more expensive, more effective, and cost-effective at $20,412 per QALY. Treatment remained cost-effective when the incremental cost to treat GDM was less than $3555 or if treatment met at least 49% of its reported efficacy at the baseline cost to treat of $1786. Conclusion: Treating mild GDM is cost-effective in terms of improving maternal and neonatal outcomes including decreased rates of preeclampsia, cesarean sections, macrosomia, shoulder dystocia, permanent and transient brachial plexus injury, neonatal hypoglycemia, neonatal hyperbilirubinemia, and neonatal intensive care unit admissions.
KW - cost-effectiveness
KW - decision analysis
KW - gestational diabetes mellitus
UR - http://www.scopus.com/inward/record.url?scp=80052207228&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80052207228&partnerID=8YFLogxK
U2 - 10.1016/j.ajog.2011.06.051
DO - 10.1016/j.ajog.2011.06.051
M3 - Article
C2 - 22071065
AN - SCOPUS:80052207228
SN - 0002-9378
VL - 205
SP - 282.e1-282.e7
JO - American journal of obstetrics and gynecology
JF - American journal of obstetrics and gynecology
IS - 3
ER -